Detemir insulin for the treatment of diabetes mellitus in dogs

Fracassi, Federico; Corradini, Sara; Hafner, M; Boretti, Felicitas S; Sieber-Ruckstuhl, N.; Reusch, Claudia E

doi:10.2460/javma.247.1.73

Cited by 21 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Though detemir's time action profile was relatively consistent amongst dogs, its duration of about 11 hours action coupled with a significant peak does not allow for once daily administration without a relatively high risk of hypoglycemia. A previous clinical trial using insulin detemir in canine diabetics has highlighted similar concerns even when used every 12 hours (at the dose used in this study), with 6 episodes of clinical hypoglycemia observed in 4 dogs in a 6-month period in one study [21].…”

Section: Endogenous and Exogenous Insulin Measurementsupporting

confidence: 52%

“…Furthermore, it has been shown that within insulin type and preparation, considerable variation exists. This results in difficulty establishing ideal doses and dosing intervals for each patient [19][20][21][22][23][24][25][26][27]. Specific insulin types are described in more detail in the following chapter.…”

Section: Chapter 2: Treatment Of Diabetes Mellitus In the Canine Patientmentioning

confidence: 99%

“…These two insulin formulations (insulin glargine 300 U/ml and insulin detemir) have similar potential in decreasing the frequency of these adverse events in diabetic canine patients. The time action profile of insulin glargine 300 U/ml has not been evaluated in dogs, and there is minimal data on the pharmacodynamics of insulin detemir in dogs [19][20][21].…”

Section: Chapter 4: Use Of Insulin Glargine and Insulin Detemir In Thmentioning

confidence: 99%

“…The time-action profile of insulin detemir has only been evaluated in three dogs, and only at doses that are likely too high to be clinically relevant (0.5 U/kg) [20]. Clinical trials using insulin detemir in canine diabetic patients have revealed it to be efficacious as a twice daily insulin choice, but have suggested a possible increased risk of hypoglycemia due to relative high potency of the product compared to other insulin formulations [21].…”

Section: Chapter 4: Use Of Insulin Glargine and Insulin Detemir In Thmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs

Fink

Herbert

Gilor

2018

Domestic Animal Endocrinology

View full text Add to dashboard Cite

Insulin glargine 300 U/mL and insulin detemir are synthetic long-acting insulin analogs associated with minimal day-to-day variability or episodes of hypoglycemia in people. Here, 8 healthy purpose-bred dogs each received 2.4 nmol/kg subcutaneous injections of insulin detemir (0.1 U/kg) and insulin glargine 300 U/mL (0.4 U/kg) on 2 different days, >1 wk apart, in random order. Blood glucose (BG) was measured every 5 min, and glucose was administered intravenously at a variable rate with the goal of maintaining BG within 10% of baseline BG ("isoglycemic clamp"). Endogenous and exogenous insulin were measured for up to 24 h after insulin injection. The effect of exogenous insulin was defined by glucose infusion rate or a decline in endogenous insulin. Isoglycemic clamps were generated in all 8 dogs after detemir but only in 4 dogs after glargine. Median time to onset of action was delayed with glargine compared to detemir (4.0 h [3.3-5.8 h] vs 0.6 h [0.6-1.2 h], P = 0.002). There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively. Glargine demonstrated a peakless time-action profile in 4/8 dogs. The total metabolic effect and peak action of detemir was significantly greater than glargine. Significant concentrations of glargine were detected in all but 1 dog following administration. Glargine might be better suited than detemir as a once-daily insulin formulation in some dogs based on its long duration of action and peakless time-action profile. Day-to-day variability in insulin action should be further assessed for both formulations.

show abstract

Section: Endogenous and Exogenous Insulin Measurementsupporting

confidence: 52%

Section: Chapter 2: Treatment Of Diabetes Mellitus In the Canine Patientmentioning

confidence: 99%

Section: Chapter 4: Use Of Insulin Glargine and Insulin Detemir In Thmentioning

confidence: 99%

Section: Chapter 4: Use Of Insulin Glargine and Insulin Detemir In Thmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs

Fink

Herbert

Gilor

2018

Domestic Animal Endocrinology

View full text Add to dashboard Cite

show abstract

“…A glicemia sérica é afetada por diversos fatores, como, por exemplo, variação diurna, exercício, estresse, alimentação e medicação, o que não ocorre com a hemoglobina glicada e a frutosamina (9) , aumentando a margem de confiança para afirmar que o cão está com glicemia elevada e por tempo prolongado (10) . Ambas as substâncias são geradas pela interação com a glicose plasmática (11,12) . Foi possível notar que a correlação mais elevada ocorreu entre a glicose e a hemoglobina glicada, resultado este observado também na comparação das avaliações entre animais sobreviventes e não sobreviventes, pois foram as únicas que mostraram resultados menores no grupo sobrevivente (Tabela 3).…”

Section: Resultsunclassified

Hemoglobina Glicada E Frutosamina Em Cães Com Diabetes Mellitus

et al. 2015

View full text Add to dashboard Cite

ResumoO Diabetes mellitus (DM) ocorre com frequência em cães, sendo a glicemia o teste laboratorial de confirmação. O diagnóstico e monitoramento em pessoas são realizados pelas concentrações de hemoglobina glicada e frutosamina. O objetivo deste estudo foi diagnosticar a DM em 19 cães, com avaliação das concentrações da glicose sérica, hemoglobina glicada e frutosamina. Seis cães com DM e em tratamento com insulina foram acompanhados por um período de doze meses, com as mesmas avaliações hematológicas, até o óbito (três cães) ou controle glicêmico (três cães). Observouse aumento dos valores de glicose, hemoglobina glicada e frutosamina em todos os cães com DM, e valores de hemoglobina glicada e glicose superiores nos animais não sobreviventes, na última avaliação realizada. Estes resultados apontam para a importância da avaliação de hemoglobina glicada e frutosamina em cães com diabetes e para diagnóstico e controle da efetividade do tratamento. Palavras-Chave: diagnóstico laboratorial; glicemia; insulina; prognóstico. AbstractDiabetes mellitus (DM) commonly occurs in dogs, and the laboratorial confirmation is carried out by glycemia test. The diagnosis and monitoring in humans is made by glycated hemoglobin and fructosamine concentrations. The objective of this study was to diagnose DM in 19 dogs, by evaluating seric glucose, glycated hemoglobin and fructosamine concentrations. Six dogs with DM and treated with insulin were assisted during a twelve-month period, by means of the same blood analysis, until the death (three dogs) or glycemic control (three dogs). Glucose, glycated hemoglobin and fructosamine increased in all dogs with DM, and dogs that did not survive presented higher glycated hemoglobin and seric glucose values than those that survived at the last evaluation. The results showed the importance of evaluating glycated hemoglobin and fructosamine in dogs with DM to diagnose and control treatment effectiveness.

show abstract

Endocrine Pharmacotherapeutics

Mealey¹

2019

Pharmacotherapeutics for Veterinary Dispensing

View full text Add to dashboard Cite

Detemir insulin for the treatment of diabetes mellitus in dogs

Cited by 21 publications

References 26 publications

Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs

Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs

Hemoglobina Glicada E Frutosamina Em Cães Com Diabetes Mellitus

Endocrine Pharmacotherapeutics

Contact Info

Product

Resources

About